Client News

Lotus Pharmaceutical Becomes Strategic Partner for the Commercialization of Formycon’s Eylea® Biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region

Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment

Affluent Medical Announces 10th Successful Human Implantation of its Artus Urinary Sphincter, Marking Completion of the Pilot Phase

Rentschler Biopharma Announces Atrategic Realignment of its Global Business Operations

Abivax Publishes 2025 Financial Calendar

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Formycon Receives EU Approval for FYB203 (Aflibercept), a Biosimilar to Eylea®, Under the Brand Names AHZANTIVE® and Baiama®